Loading
A phase 1/2 trial of panitumumab in pancreatic cancer, run by George Poultsides, now recruiting.
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery is a phase 1/2, interventional study registered as NCT03384238 by George Poultsides, with a registry enrolment figure of 27 participants, started 2018-02-07 and due to reach its primary completion in 2027-03. Interventions recorded: Fluorescence Imaging; Panitumumab; Panitumumab-IRDye800. Conditions listed: Pancreatic Adenocarcinoma. Primary outcome: Tumor to background ratio (TBR). Pancreatic eligibility wording from the registry: "* Clinically suspected or biopsy-confirmed diagnosis of pancreatic adenocarcinoma". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.